| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0acc7fd312a68983fb8b9d120043467e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_29b632692b06d615bdc9b6031a350b3a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-551 |
| filingDate |
2018-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0408aa25d72d33e0c466eb2caddafde
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41d5cc9c32917acb4b5b81760a0ac04b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cfa2b8d6904deb47ce7be34a6fb75dbb |
| publicationDate |
2020-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3664807-A2 |
| titleOfInvention |
Methods and materials for identifying and treating bet inhibitor-resistant cancers |
| abstract |
The present invention provides methods and materials involved in the identification and treatment of mammals with BET inhibitor-resistant cancer. For example, the invention provides methods and materials for administering one or more AKT inhibitors in combination with one or more BET inhibitors to mammals identified as having cancer resistant to treatment with one or more BET inhibitors. absence of AKT inhibitors. |
| priorityDate |
2017-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |